Yposkesi Joins BioPhorum – Global Cell and Gene Therapy Consortium
Yposkesi, a best-in-class Contract Development and Manufacturing Organization (CDMO) for companies developing cell and gene therapies, today announces its membership of BioPhorum, Cell and Gene Therapy (CGT) Phorum. BioPhorum is a global consortium that brings together biopharmaceutical manufacturers and suppliers to discuss and work collaboratively on issues and challenges of mutual interest in the industry.
As biologics derive from living organisms, their manufacture is highly complex. Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency, whilst operating within a rapidly evolving regulatory environment, as well as responding to market pressures for commercializing cell and gene therapies within shorter timeframes.
“Given the burgeoning state of bioprocessing for cell and gene therapies, many companies, including Yposkesi, are confronting the same issues. Yet we are working on them in isolation. It makes more sense to work together to solve these problems in a more time-efficient and consistent way,” remarked Brian Mullan, head of innovation, analytical and process development at Yposkesi. “BioPhorum has a well-established reputation as a collaborative, proactive and productive forum to develop solutions to common problems in the bioprocessing sector. As a new member, we look forward to engaging in collaborations to achieve this objective.”
CGT Phorum membership covers access to, and participation in, various workstreams and teams focused on different thematics important to the industry (e.g. process validation, analytics, regulatory).
Besides its expertise in developing Adeno-Associated Virus (AAV) and Lentiviral Vector (LV) manufacturing platforms, Yposkesi will bring to BioPhorum its experience in applying these to a wide range of projects for its global clients. Yposkesi will also be able to offer extensive expertise in CGT technical development and manufacturing.
“BioPhorum is delighted to welcome Yposkesi as a member of the Cell & Gene Therapy Phorum,” said Louis Bennett, CGT Phorum lead. “We look forward to collaborating with its experts on the key CGT industry priorities. The expertise in AAV and Lentiviral methodologies that Yposkesi brings will enhance the discussions across the member companies and support development of innovative approaches to support the industry.”
People In This Post
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more